The expected arrival of generic versions of semaglutide -- the active ingredient in Ozempic and Wegovy -- is poised to force a rethink of how Canadian insurers handle obesity treatments.
At present, provincial and territorial drug plans only reimburse Ozempic for people with type 2 diabetes, even though it is widely prescribed off-label for weight loss. Coverage for obesity alone is rare and tightly restricted. That has left many patients paying out of pocket or abandoning therapy early when they can’t afford to stay on the medication.
Public spending on prescriptions climbed to $20.1 billion in 2024, with growing Ozempic use a visible contributor, according to a report from The Globe and Mail. If lower‑priced generics come to market, both public plans and private insurers will have less room to argue that GLP‑1s are simply too expensive to fund.
Ottawa obesity specialist Yoni Freedhoff estimated that generic GLP‑1s could cost in the region of $1,000 per patient per year, and potentially less after negotiations with public drug plans. That is still substantial but far below current list prices for brand‑name semaglutide, the report said.
At that price point, the financial argument against coverage weakens when weighed against downstream costs of untreated obesity, including type 2 diabetes, cardiovascular disease and related disability. Freedhoff points to potential reductions in absenteeism, comorbidities, disability claims and hospitalizations, and said it is “impossible to imagine” payers staying out of the space indefinitely. He predicts some form of broad coverage is “an inevitability,” whether led by employers, governments or both.
For actuaries and plan designers, however, a lower unit cost raises a different concern: volume. Roughly one in three Canadian adults meets clinical criteria for obesity, the report said. If even a modest share of that population qualifies for GLP‑1 therapy and treatment is long term, total drug spend could rise sharply, even with generics.
According to the report, about two-thirds of Canadians have private drug coverage, with the remainder relying on public plans or pay out of pocket.
Alberta is the only province to formally recognize obesity as a chronic disease, and it still does not cover GLP‑1s specifically for weight management. Elsewhere, public coverage is generally limited to diabetes.
Obesity experts argue that once generics arrive, public plans will face strong pressure to expand access, particularly for patients with multiple obesity‑related conditions. Sanjeev Sockalingam, scientific director of Obesity Canada, expects provinces to wrestle with eligibility rules.
Sockalingam said BMI should be treated as a screening tool rather than a sole gatekeeper, with other factors such as diabetes, hypertension and sleep apnea considered in coverage decisions.
The pan‑Canadian Pharmaceutical Alliance, which negotiates on behalf of federal, provincial and territorial drug plans, has indicated it will consider negotiations on semaglutide once a generic is approved by Health Canada. Talks with Novo Nordisk over Wegovy collapsed in December after the manufacturer declined to negotiate on price, underlining how central cost will be to any broader funding, the news outlet reported.
For private health insurers and employer plans, generic semaglutide could accelerate a shift away from treating obesity medication as an elective “lifestyle” category toward chronic disease management.
Many group plans have traditionally excluded weight‑loss drugs. That stance sits uneasily with the position of major medical bodies in Canada and abroad, which now classify obesity as a chronic disease requiring ongoing treatment. As more patients seek GLP‑1 coverage and clinicians frame these therapies as standard of care for high‑risk patients, pressure on plan sponsors is likely to grow.
Carriers will need to decide how tightly to control access – for example, through prior authorization, documentation of failed lifestyle interventions, and requirements for ongoing clinical review. They will also have to consider how GLP‑1 coverage interacts with disability and life insurance, given the potential for these drugs to reduce the incidence and severity of cardiometabolic conditions that drive high‑cost claims.
At the same time, insurers will be wary of unintended consequences. Sockalingam and others warn that obesity pharmacotherapy can intersect with eating disorders and mental‑health conditions, which may worsen if medications are used without proper screening and support. That points to the need for integrated care models that combine medication with psychological and nutritional support, rather than a simple formulary add.
Most provinces said they are waiting on Health Canada approvals before taking positions on generic semaglutide coverage. The federal Non‑Insured Health Benefits Program for First Nations and Inuit is monitoring the negotiating process. No generic semaglutide has yet been authorized, the report said.
Once that changes, however, payers will face a more explicit decision on whether to treat obesity as an insurable chronic disease on par with diabetes and hypertension, or continue to limit pharmacologic options to a narrow subset of patients.
If generics land at the price levels clinicians predict, GLP‑1s are likely to move from the edge of Canadian drug plans to the center of discussions about chronic disease management, cost control and health equity. How quickly insurers respond – and how carefully they design coverage – will shape both claim trends and public expectations in the coming years.
